On 30 November, Carmat announced that the first patient implanted with its bioprosthetic heart as part of its European pivotal trial has died. The implantation occurred in late August and press sources report that the death was in October. The company’s analyses do not suggest the prosthesis was responsible for the death, although the French regulatory agency (ANSM) is suspending future Carmat implantations. Our valuation (previous rNPV of €747m) is under review.
01 Dec 2016
Regulatory agency suspends Carmat implants
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Regulatory agency suspends Carmat implants
Carmat SA (ALCAR:PAR) | 0 0 0.7% | Mkt Cap: 195.7m
- Published:
01 Dec 2016 -
Author:
Pooya Hemami -
Pages:
2
On 30 November, Carmat announced that the first patient implanted with its bioprosthetic heart as part of its European pivotal trial has died. The implantation occurred in late August and press sources report that the death was in October. The company’s analyses do not suggest the prosthesis was responsible for the death, although the French regulatory agency (ANSM) is suspending future Carmat implantations. Our valuation (previous rNPV of €747m) is under review.